NASDAQ:CDXS

Codexis Competitors

$24.55
+0.02 (+0.08 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.08
Now: $24.55
$24.89
50-Day Range
$18.08
MA: $22.04
$25.46
52-Week Range
$10.03
Now: $24.55
$29.56
Volume354,334 shs
Average Volume708,651 shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.17

Competitors

Codexis (NASDAQ:CDXS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying CDXS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Codexis, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Codexis (NASDAQ:CDXS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$68.46 million23.09$-11,940,000.00($0.21)-116.90
Amgen$23.36 billion6.29$7.84 billion$14.8217.22

Amgen has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codexis-31.08%-21.25%-14.33%
Amgen29.42%95.55%15.52%

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codexis00503.00
Amgen091402.61

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Amgen has a consensus price target of $261.0476, suggesting a potential upside of 2.32%. Given Codexis' stronger consensus rating and higher possible upside, research analysts plainly believe Codexis is more favorable than Amgen.

Summary

Amgen beats Codexis on 8 of the 14 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$68.46 million23.09$-11,940,000.00($0.21)-116.90
Gilead Sciences$22.45 billion3.69$5.39 billion$6.1410.71

Gilead Sciences has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codexis-31.08%-21.25%-14.33%
Gilead Sciences5.48%37.77%12.76%

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codexis00503.00
Gilead Sciences191302.52

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Gilead Sciences has a consensus price target of $97.92, suggesting a potential upside of 48.88%. Given Gilead Sciences' higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Codexis.

Summary

Gilead Sciences beats Codexis on 9 of the 14 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$68.46 million23.09$-11,940,000.00($0.21)-116.90
Vertex Pharmaceuticals$4.16 billion13.75$1.18 billion$4.2951.54

Vertex Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codexis-31.08%-21.25%-14.33%
Vertex Pharmaceuticals38.51%28.55%20.68%

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codexis00503.00
Vertex Pharmaceuticals042112.88

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Vertex Pharmaceuticals has a consensus price target of $293.1250, suggesting a potential upside of 32.58%. Given Vertex Pharmaceuticals' higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Codexis.

Summary

Vertex Pharmaceuticals beats Codexis on 11 of the 15 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$68.46 million23.09$-11,940,000.00($0.21)-116.90
Regeneron Pharmaceuticals$7.86 billion6.74$2.12 billion$21.4723.04

Regeneron Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codexis-31.08%-21.25%-14.33%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codexis00503.00
Regeneron Pharmaceuticals051412.80

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Regeneron Pharmaceuticals has a consensus price target of $646.2609, suggesting a potential upside of 30.65%. Given Regeneron Pharmaceuticals' higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Codexis.

Summary

Regeneron Pharmaceuticals beats Codexis on 11 of the 15 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Codexis and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$68.46 million23.09$-11,940,000.00($0.21)-116.90
Biogen$14.38 billion2.87$5.89 billion$33.578.06

Biogen has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codexis-31.08%-21.25%-14.33%
Biogen35.63%51.00%23.54%

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codexis00503.00
Biogen5141202.23

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Biogen has a consensus price target of $303.5862, suggesting a potential upside of 12.26%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Codexis.

Summary

Biogen beats Codexis on 9 of the 14 factors compared between the two stocks.

Codexis (NASDAQ:CDXS) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Insider & Institutional Ownership

91.3% of Codexis shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 10.2% of Codexis shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Codexis and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codexis00503.00
Alexion Pharmaceuticals017512.30

Codexis currently has a consensus price target of $26.60, suggesting a potential upside of 8.35%. Alexion Pharmaceuticals has a consensus price target of $153.8636, suggesting a potential downside of 2.33%. Given Codexis' stronger consensus rating and higher possible upside, research analysts plainly believe Codexis is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Codexis and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$68.46 million23.09$-11,940,000.00($0.21)-116.90
Alexion Pharmaceuticals$4.99 billion6.94$2.40 billion$9.7416.17

Alexion Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Codexis and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codexis-31.08%-21.25%-14.33%
Alexion Pharmaceuticals16.32%23.16%14.76%

Risk and Volatility

Codexis has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Codexis on 9 of the 14 factors compared between the two stocks.


Codexis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.13+2.2%$146.90 billion$23.36 billion20.58Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.77+0.7%$82.81 billion$22.45 billion67.80Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$221.10+1.8%$57.23 billion$4.16 billion27.92
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$494.64+2.7%$52.99 billion$7.86 billion18.08Analyst Report
Biogen logo
BIIB
Biogen
1.9$270.44+1.7%$41.20 billion$14.38 billion8.95Upcoming Earnings
Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$157.54+1.4%$34.63 billion$4.99 billion36.81Unusual Options Activity
Seagen logo
SGEN
Seagen
1.5$149.64+3.6%$27.13 billion$916.71 million58.91Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.52+2.6%$22.07 billion$876.29 million-59.06
Incyte logo
INCY
Incyte
1.7$83.20+1.2%$18.29 billion$2.16 billion-52.99
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$139.02+0.5%$16.31 billion$219.75 million-17.75
Novavax logo
NVAX
Novavax
1.4$202.09+0.4%$14.93 billion$18.66 million-38.71
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.77+0.7%$14.32 billion$1.70 billion18.03
Repligen logo
RGEN
Repligen
1.5$213.57+3.9%$11.70 billion$270.24 million260.45
United Therapeutics logo
UTHR
United Therapeutics
1.5$201.67+0.6%$8.98 billion$1.45 billion19.08Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.00+0.1%$8.98 billion$788.10 million102.15Analyst Upgrade
Increase in Short Interest
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$23.95+0.4%$7.47 billion$967.78 million49.90
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.20+0.5%$6.62 billion$195.99 million288.75Insider Selling
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.03+1.9%$5.78 billion$1.12 billion85.48
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.99+0.5%$4.10 billion$806.43 million-9.63Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47+0.0%$3.99 billion$1.11 billion23.95Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.15+0.4%$3.29 billion$36.13 million-70.37
Alkermes logo
ALKS
Alkermes
1.2$19.77+2.7%$3.15 billion$1.17 billion-42.98
OPKO Health logo
OPK
OPKO Health
1.9$4.32+2.8%$2.89 billion$901.90 million-24.00
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.33+3.4%$2.73 billion$182.24 million-8.98Analyst Upgrade
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.88+1.4%$2.47 billion$120.28 million-150.38Analyst Report
Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.76+2.9%$2.16 billion$638.60 million-11.06
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$126.65+4.5%$2.03 billionN/A-11.44
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.34+10.1%$2.01 billion$48.83 million-14.92Analyst Report
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.84+1.9%$1.74 billion$428.41 million15.71News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.77+1.1%$1.69 billion$102.43 million-19.62
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.70+1.0%$1.54 billion$82.27 million-18.78
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.86+6.6%$1.23 billion$35.22 million-7.93
Innoviva logo
INVA
Innoviva
1.4$11.89+1.2%$1.21 billion$261.02 million6.07
Curis logo
CRIS
Curis
1.1$12.21+2.8%$1.12 billion$10 million-14.89Increase in Short Interest
MannKind logo
MNKD
MannKind
1.4$4.30+6.0%$1.07 billion$63.04 million-20.48Increase in Short Interest
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.56+5.5%$933.33 million$3.57 million-10.56Analyst Upgrade
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.78+2.0%$920.94 million$227.19 million46.61Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.33+1.5%$883.86 millionN/A0.00Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.21+0.4%$752.08 million$322.07 million-4.96Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.43+0.9%$737.08 million$150,000.00-4.89
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.55+4.2%$678.48 million$252 million-2.10High Trading Volume
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.78+1.3%$643.06 million$59.29 million-25.20Increase in Short Interest
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.10+2.5%$637.63 million$143.01 million-1.16
Agenus logo
AGEN
Agenus
1.6$2.66+1.1%$544.46 million$150.05 million-2.44
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.71+5.3%$488.21 million$22.27 million-4.27Analyst Report
Insider Buying
Analyst Revision
Geron logo
GERN
Geron
1.4$1.51+0.0%$480.98 million$460,000.00-4.31Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.3$2.69+0.4%$461.78 million$17.46 million-1.91
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.98+0.0%$458.11 million$109.33 million-2.19
XOMA logo
XOMA
XOMA
1.3$37.85+1.3%$426.12 million$18.37 million-34.10Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.44+2.3%$421.39 million$36.63 million-5.22
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.